Chevy Chase Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Chevy Chase Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-528	Closed	-$79K	–	823
2019 Q4	$79K	Buy	+528	New	+$71.9K	﹤0.01%	756

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Chevy Chase Trust's JAZZ Position: Q1 2020 in Review

Chevy Chase Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 528 shares — an estimated $79K sold.

Chevy Chase Trust first reported a position in JAZZ in Q4 2019 and held it in 1 quarter. The position peaked at $79K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Chevy Chase Trust reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Chevy Chase Trust sold 528 Jazz Pharmaceuticals shares in Q1 2020, an estimated $79K.
Chevy Chase Trust first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Chevy Chase Trust's Jazz Pharmaceuticals position peaked at $79K in Q4 2019.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Chevy Chase Trust's 13F filing for Q1 2020, filed 13 May 2020.